European CHMP recommends paediatric license extension of atazanavir / cobicistat (Evotaz) for treatment of HIV

The proposed license extension is in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir.

European Medicines Agency